Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

naptumomab estafenatox

A recombinant fusion protein consisting of the antigen-binding fragment of a monoclonal antibody directed towards the tumor-associated oncofetal… Expand
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (1)

ABR-217620

Broader (3)

EnterotoxinsImmunoconjugatesMonoclonal Antibodies
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis
Purpose: To prospectively determine the efficacy of naptumomab estafenatox (Nap) + IFNα versus IFN in metastatic renal cell… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
2015
2015
Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α
Naptumomab estafenatox/ABR-217620/ANYARA (Nap) has been evaluated in clinical phase 1 and 2/3 studies. RCC patients in the phase… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Review
2014
Review
2014
Naptumomab Estafenatox: Targeted Immunotherapy with a Novel Immunotoxin
Improvement of cancer therapy by introducing new concepts is still urgent even though there have been major advancements lately… Expand
  • figure 1
  • table 1
2013
2013
A randomized phase II/III study of naptumomab estafenatox plus IFN-α versus IFN-α in advanced renal cell carcinoma.
3073 Background: Naptumomab estafenatox/ANYARA (Nap) is a fusion protein of an antibody (5T4) and a superantigen (SEA/E-120… Expand
2013
2013
The Tumor Targeted Superantigen ABR-217620 Selectively Engages TRBV7-9 and Exploits TCR-pMHC Affinity Mimicry in Mediating T Cell Cytotoxicity
The T lymphocytes are the most important effector cells in immunotherapy of cancer. The conceptual objective for developing the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2010
2010
Naptumomab Estafenatox, an Engineered Antibody-superantigen Fusion Protein With Low Toxicity and Reduced Antigenicity
Antibody-targeted superantigens have a potential to become useful drugs for tumor therapy. However, clinical practice has… Expand
2010
2010
Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials
Traditionally, the major objective in phase I trials is to identify a working-dose for subsequent studies, whereas the major… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Review
2010
Review
2010
Naptumomab estafenatox: a new immunoconjugate
Importance of the field: New agents that specifically engage the immune system are being tested in a variety of malignancies… Expand
Highly Cited
2009
Highly Cited
2009
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung…
PURPOSE Two phase I studies were conducted of ABR-217620 alone or in combination with docetaxel. This is a recombinant fusion… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
2006
2006
An open label phase I study of ABR-217620, a fusion protein of the 5T4 antibody moiety and an engineered superantigen, in patients with non-small cell lung, renal cell or pancreatic cancer.
3083 Background: ABR-217620 (naptumomab estafenatox) is a recombinant fusion protein that consists of the 5T4Fab moiety… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE